MUNICH, July 16 (Reuters) - German packaging and medical

equipment maker Gerresheimer has ended discussions on

a potential sale of the company after months of talks since the

start of 2025, it said on Wednesday evening.

In February the Duesseldorf-based company had said it was in

early discussions with private equity investors over a potential

sale, with KPS Capital Partners and Warburg Pincus among the

possible buyers.

Among Gerresheimer activities to catch attention is its

production of pens used for injecting weight-loss medication

such as Novo Nordisk's Wegovy.

"After a thorough analysis ... the company believes that

continuing the discussions is not in the best interest of the

company and its stakeholders," Gerresheimer's statement said.

Gerresheimer shares fell 6% in late trading on Tradegate

after the announcement.

The company has struggled in the face of weak demand in

cosmetics and oral liquids markets, which led it to cut the

lower end of its revenue growth forecast for 2025 last week, now

estimating a range of 0-2% growth, down from the previous range

of 1% to 2%.

The company will, however, provide a strategic review of its

moulded glass business on October 15, it said, a segment that it

could decide to spin off.

In the medium term, Gerresheimer expects organic revenue

growth of 6-9% and an organic adjusted EBITDA margin of 23-25%,

it said in Wednesday's statement.